• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 04, 2023 at 10:42: AM
via The impressive performance of Eli Lilly’s donanemab in the Phase III TRAILBLAZER-ALZ 2 study has reignited the biopharma industry’s interest in Alzheimer’s disease, triggering stock gains for several drug developers in the space.

article source
 

<



Similar threads

cafead
Lilly gets a date with FDA to discuss Alzheimer&#039;s med donanemab
Replies
0
Views
53
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Some Experts Say FDA Made the Right Call on Lilly&#039;s Donanemab
Replies
0
Views
237
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eli Lilly kick-starts speedy FDA review for Alzheimer&#039;s hopeful donanemab—and a...
Replies
0
Views
150
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves Eli Lilly&#039;s drug for eczema
Replies
0
Views
5
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
&#039;We&#039;re pretty prolific&#039;: Lilly Catalyze360 looks to connect with emerging biotechs across &#039;all areas&#039;
Replies
0
Views
25
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote